Rubato
- Company typePrivate
- Founded2020
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Rubato does
Rubato is a Los Angeles-based health technology company that has built an AI-driven, physiology-informed music-based intervention (MBI) platform — branded as Rubato Life — for seniors living with dementia, Alzheimer's disease and related dementias (ADRD), and mild cognitive impairment (MCI). The platform continuously monitors real-time cardiac rhythms and stress biomarkers to anticipate behavioral escalation, then uses proprietary music attribute analysis (key, tempo, genre, artist, structure) and a per-patient learning loop to generate personalized therapeutic playlists delivered via tablet. Rubato positions the intervention as fully reimbursable under Medicare Part B through applicable CPT codes, targeting Skilled Nursing Facilities (SNFs), rehabilitation centers, and post-acute care providers as its primary customer base.
The company's go-to-market is a sales-led B2B enterprise motion: Account Executives drive new SNF acquisition through cold outreach, demos, and relationship building with facility administrators, therapy directors, and financial officers, while Clinical Support Specialists deliver hands-on therapist training and onboarding. Clinical credibility is anchored by three academic relationships — an NIH-funded study at Brown University, an anxiety-focused clinical study with Boston University, and a peer-reviewed oncology publication with the University of Illinois — that support broader applicability beyond dementia care.
Rubato generates revenue through B2B facility licensing with a recurring subscription-style structure aligned to Medicare Part B reimbursement cycles, though specific contract values and total revenue are not publicly disclosed. The company was incorporated in Delaware (privacy policy dated December 2019) and is venture-backed following a 2022 round involving Techstars, 97212 Ventures, and The Mercantile Companies; ownership is concentrated in co-founders Amit Sternberg (CEO) and Noam Guy (CTO), supported by a Clinical Advisory board.
Rubato firmographics
Firmographics- Name
- Rubato
- Legal name
- Rubato, Inc.
- Website
- https://rubato.life
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Rubato industry classification
Industry- Product category
- Digital Health / AI Therapeutic Platform for Dementia Care
- NAICS
- Offices of Physicians, Mental Health Specialists (621112), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
- akta.pro secondary industry
- Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
Keywords
Where Rubato is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rubato business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Medicare Part B Reimbursement: Rubato's music-based intervention is fully reimbursable for eligible patients at Skilled Nursing Facilities through Medicare Part B using applicable CPT codes. This provides a recurring revenue stream from healthcare facilities treating long-term patients.
- B2B Platform Licensing to Skilled Nursing Facilities: Direct B2B sales of the AI-powered music therapy platform to skilled nursing facilities, rehabilitation centers, and post-acute care providers. Revenue generated through facility licensing and implementation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Reimbursable intervention for Medicare Part B eligible patients |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Rubato product offering
Product offeringCore offering
Rubato sells the Rubato Life platform, an AI-driven, physiology-informed music-based intervention (MBI) that continuously monitors cardiac rhythms and stress biomarkers in dementia and cognitive impairment patients, learns each patient's effective musical attributes, and delivers personalized therapeutic playlists via tablet in Skilled Nursing Facilities. The intervention is fully reimbursable under Medicare Part B through applicable CPT codes and is clinically validated through NIH-funded research at Brown University and clinical studies with Boston University and the University of Illinois.
Product overview
Rubato offers a single unified product: the Rubato Life platform, an AI-driven music-based intervention (MBI) system. The platform consists of a personalized AI system that analyzes cardiac rhythms and stress levels, evaluates music attributes (key, tempo, genre, artist), and delivers physiology-driven therapeutic music interventions via tablet to support dementia patients in skilled nursing facilities. The intervention is fully reimbursable under Medicare Part B and is backed by clinical outcomes data and research validation from Brown University, Boston University, and University of Illinois.
Differentiator
Problem solved
Functional benefit
Products and services
- Rubato Life Platform AI-driven, physiology-informed music-based intervention (MBI) platform that continuously monitors physiological patterns associated with stress and behavioral escalation, learns which musical attributes (tempo, genre, language, structure) are most effective for each individual patient, and delivers personalized therapeutic playlists via tablet. Sold B2B to Skilled Nursing Facilities and post-acute care providers and fully reimbursable under Medicare Part B via applicable CPT codes for long-term patients.
Quantifiable outcome
- Significant reduction in stress during pre-post measurement on cancer patients
- +4 more outcomes
Companies that use Rubato
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Rubato technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Rubato partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Brown UniversityflagshipRubato is the technology partner in an NIH-funded study at Brown University investigating how real-time physiological patterns can inform timely, responsive music-based interventions for behavioral regulation in dementia care. This is a major validation partnership for the company's clinical approach.
- Boston UniversitycoreClinical study with Boston University using STAI questionnaires showed significant improvements in anxiety among participants receiving Rubato's music-based intervention. Research validates the platform's effectiveness in reducing anxiety.
- University of IllinoiscorePeer-reviewed study published in a leading oncology journal found that Rubato's intervention helped reduce anxiety and improve quality of life in cancer patients. Study demonstrates broader applicability beyond dementia care.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Rubato competitors and assessment
Company assessmentDirect peers
- Constant Therapy Health: Constant Therapy delivers a digital cognitive, speech, and language therapy platform used in rehabilitation and skilled nursing settings by occupational, speech, and physical therapists. It overlaps with Rubato on the SNF therapist buyer persona and AI-driven therapy delivery model.
- Neuroglee Therapeutics: Neuroglee develops digital therapeutics specifically for patients with mild cognitive impairment and early dementia, combining software-based cognitive therapy with caregiver support. It targets a similar patient population and clinical indication (cognitive impairment / dementia) using a digital therapeutic delivery model.
- Coro Health: Coro Health provides therapeutic music, video, and wellness content products for senior living, skilled nursing, and hospice settings. It directly competes with Rubato in offering music-based therapeutic content to dementia and cognitive-impairment populations in SNFs.
- Musical Health Technologies (SingFit): SingFit is a music therapy platform specifically designed for older adults, including those with dementia, in senior living and care settings. It is the most directly comparable competitor, addressing the same clinical use case (music-based intervention for cognitive and behavioral symptoms) with a similar SNF/senior-care go-to-market motion.
Emerging players
- Linus Health: Linus Health offers digital cognitive assessment and brain health platforms focused on early detection of dementia and cognitive impairment. It is comparable as an emerging digital health player targeting the same dementia diagnostic and management pathway.
- Altoida: Altoida develops digital cognitive biomarkers and AI-driven assessments for early detection of Alzheimer's disease and other dementias. It targets the same clinical population (cognitive impairment / dementia) using AI on physiological and behavioral data.
- Isaac Health: Isaac Health provides dementia-focused virtual care, cognitive assessment, and care navigation services, often partnering with health systems and senior populations. It overlaps with Rubato in the dementia patient population and use of technology-enabled clinical workflows.
Broad incumbents
- Posit Science (BrainHQ): Posit Science's BrainHQ is an established cognitive training platform used across senior care, health systems, and research settings. It is a broader incumbent in computerized cognitive intervention, overlapping with Rubato's goal of slowing or managing cognitive decline in older adults.
- Cogstate: Cogstate provides computerized cognitive testing and assessment tools widely used in clinical trials, healthcare, and research for dementia and cognitive impairment. It is a broader incumbent in the cognitive measurement and dementia assessment category that Rubato's clinical workflow touches.
Others
- Biobeat: Biobeat manufactures wearable remote patient monitoring devices that capture continuous cardiac and physiological biomarkers. Rubato uses similar real-time cardiac rhythm monitoring inputs in its platform, making Biobeat a relevant enabling/infrastructure peer for the physiological monitoring layer.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Rubato social profiles
Digital presenceRubato financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rubato leadership team
Management profileNumber of profiles
Profiles2 records
Rubato funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rubato M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rubato
What does Rubato do?
Rubato sells the Rubato Life platform, an AI-driven, physiology-informed music-based intervention (MBI) that continuously monitors cardiac rhythms and stress biomarkers in dementia and cognitive impairment patients, learns each patient's effective musical attributes, and delivers personalized therapeutic playlists via tablet in Skilled Nursing Facilities. The intervention is fully reimbursable under Medicare Part B through applicable CPT codes and is clinically validated through NIH-funded research at Brown University and clinical studies with Boston University and the University of Illinois.
Is Rubato a public or private company?
Rubato is a private company. It is classified as venture growth investor backed and is currently operating.
When was Rubato founded?
Rubato was founded in 2020. It employs 1 to 10 people.
Where is Rubato based?
Rubato is headquartered in Los Angeles, United States, in the North America region.
How does Rubato make money?
Two revenue lines are on record. Medicare Part B Reimbursement is the primary driver. The others are B2B Platform Licensing to Skilled Nursing Facilities.
Who are Rubato's main competitors?
Direct peers on record are Constant Therapy Health, Neuroglee Therapeutics, Coro Health and Musical Health Technologies (SingFit). Emerging players are Linus Health, Altoida and Isaac Health. Broad incumbents are Posit Science (BrainHQ) and Cogstate. Biobeat is listed as an others.
Does Rubato have an API?
No public API is recorded for Rubato.
What industry is Rubato in?
Rubato's product category is Digital Health / AI Therapeutic Platform for Dementia Care. Its primary akta.pro industry code is HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs), with a secondary code of HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders). Its NAICS code is 621112 and its SIC code is 8090.